Products - Prostate cancer | Topic

Showing 19 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 November 2022
Focal therapy using high-intensity focused ultrasound for localised prostate cancer
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
5 April 2023
MRI fusion biopsy in people with suspected prostate cancer
Status:
In development
Programme:
Diagnostics guidance
Expected publication date:
17 May 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 May 2023
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (hormone refractory) - atrasentan [ID390]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (prevention) - dutasteride [ID75]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Status:
In development
Programme:
Medical technologies guidance
Expected publication date:
TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Transperineal biopsy for diagnosing prostate cancer
Status:
In development
Programme:
Diagnostics guidance
Expected publication date:
TBC
Irreversible electroporation for treating prostate cancer
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC

Prostate cancer Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 19 products

Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Focal therapy using high-intensity focused ultrasound for localised prostate cancer

MRI fusion biopsy in people with suspected prostate cancer

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]

Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

Prostate cancer (hormone refractory) - atrasentan [ID390]

Prostate cancer (prevention) - dutasteride [ID75]

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]

Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Transperineal biopsy for diagnosing prostate cancer

Irreversible electroporation for treating prostate cancer

Prostate cancer Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 19 products

Status
1 selected